Consorci Hospital General Universitari de Valencia, Valencia, Spain.
Consorci Hospital General Universitari de Valencia, Valencia, Spain.
Can J Cardiol. 2021 Jun;37(6):938.e3-938.e6. doi: 10.1016/j.cjca.2020.10.008. Epub 2020 Oct 24.
Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalisation of prosthetic valve function was observed. This case supports current recommendations of administering full-dose anticoagulation therapy to COVID-19 patients with biological heart valve prosthesis, even after the acute phase of infection.
COVID-19 患者可能出现高凝状态，对发病率和死亡率有重要影响。由于这种情况，肺栓塞是感染过程中的常见并发症。我们报告了一例患者的病例，该患者最近出院，因确诊 COVID-19 入院，随后发生了肺栓塞和生物二尖瓣假体血栓形成，导致瓣膜阻塞和狭窄。抗凝治疗 15 天后，观察到血栓溶解，假体瓣膜功能恢复正常。该病例支持目前的建议，即对 COVID-19 合并生物心脏瓣膜假体的患者给予全剂量抗凝治疗，甚至在感染的急性期之后也是如此。
